Drug patents cause fresh spat between South Africa and industryBMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g1377 (Published 07 February 2014) Cite this as: BMJ 2014;348:g1377
- Andrew Jack, deputy editor, analysis
- 1Financial Times, London, UK
Nearly 15 years after the pharmaceutical industry was accused of unwisely picking a fight with Nelson Mandela over affordable access to medicines, it is at the centre of a fresh spat concerning patents in South Africa.
Last month, Aaron Motsoaledi, the health minister, accused drug companies of “genocide” after seeing their plans to campaign against draft government proposals on intellectual property reforms. “This document can sentence many South Africans to death,” he told the Mail & Guardian.1
The inflammatory rhetoric has made industry executives and even some activists squirm, yet it comes against the backdrop of spring elections in which the ruling African National Congress is fighting to retain its political dominance.
It also reflects a broader international battle over intellectual property rights, pitching industry claims that tougher patent rules will encourage investment and innovation against patient organisations, which argue that they restrict competition and keep prices unaffordably high.
The latest feud has already had repercussions for industry, with Novo Nordisk, the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial